DoD FY11 Prostate Cancer Health Disparity Research Award

Post Date

April 21st 2011

Application Due Date

June 8th 2011

Funding Opportunity Number

W81XWH-11-PCRP-HDRA

CFDA Number(s)

12.420

Funding Instrument Type(s)

Cooperative Agreement
Grant

Funding Activity Categories

Science and Technology and other Research and Development

Number of Awards

5

Eligibility Categories

Unrestricted

Funding

• Estimated Total Funding:

  $3600000

• Award Range:

  $0 - $0

Grant Description

The PCRP Health Disparity Research Award mechanism was introduced in FY01. Since then, 177 applications have been received, and 45 have been recommended for funding. The Health Disparity Research Award supports new ideas for prostate cancer health disparity research with the potential to make an important contribution towards eliminating death and suffering from prostate cancer. The Health Disparity Research Award reflects the PCRP╔к_s commitment to reduce and ultimately eliminate disparities in prostate cancer incidence, morbidity, and mortality. Studies proposed for this award mechanism are expected to improve the understanding of, and ultimately eliminate, prostate cancer health disparities. Applicants for this award must explicitly state how the proposed research is related to an area of prostate cancer health disparity. Appropriate health disparity areas include, but are not limited to, race and ethnicity, socioeconomic status, access to health care, insurance status, age, geography, and cultural beliefs. The PCRP seeks Health Disparity Research Award applications from the wide spectrum of basic to clinical research, provided they are appropriately focused on an issue of prostate cancer health disparity. In addition, all applications (1) should be relevant to at least one of the PCRP focus areas, and (2) are encouraged, although not required, to be responsive to one of the PCRP overarching challenges. Research involving human subject use is permitted under this funding opportunity, but is restricted to studies without clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/. Principal Investigators (PIs) seeking funding for a clinical trial should consider submitting an application for the FY11 PCRP Clinical Trial Award. PIs wishing to apply for funding for population-based studies may also consider submitting an application for the FY11 PCRP Population-Based Research Award; each research project may be submitted to only one award mechanism. The Health Disparity Research Award offers two additional options for PI consideration: 1) Qualified Collaborator Option: This award mechanism strongly supports collaborative research involving basic and clinical researchers, researchers with prostate cancer expertise and those with health disparity expertise, or researchers and community organizations that may be critical to the study of populations disproportionately affected by prostate cancer. Although these and other types of collaboration are, in general, strongly encouraged, collaborations that meet specific criteria will qualify for a higher level of funding as described in Section I.D., Funding. For the application to qualify for a higher level of funding, the PI must submit a Qualified Collaboration Statement that clearly describes the collaborator and addresses how each of the criteria below are met. In addition, the collaborator must provide a letter of collaboration describing his/her involvement in the proposed work. It should be clear that the success of the project depends on the unique skills and contributions of both the PI and the qualified collaborator. The following criteria must be met to use the Qualified Collaborator Option: ╔к_ The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement. This is expected to include both intellectual input and research resources (e.g., supplies, reagents, equipment, personnel, services, tissue samples, or access to patients). ╔к_ The collaborator must contribute at least a 10% level of effort to the project. Contribution of the collaborator should be reflected in the application budget. ╔к_ If the PI does not have experience in prostate cancer research or working with disproportionately affected populations, the collaborator must possess such experience. 2) New Investigator Option: This award mechanism encourages applications from investigators in the early stages of their careers. The New Investigator Option is designed to allow applicants, early in their faculty appointments or in the process of developing independent research careers, to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed in separate groups. PIs using the New Investigator Option are strongly encouraged to strengthen their applications by including investigators experienced in prostate cancer research and/or possessing other relevant expertise as demonstrated by a record of funding and publications. It is the responsibility of the applicant to describe how additional investigators will augment the PI╔к_s expertise and better address the research question. Applicants may choose to employ both the New Investigator Option and the Qualified Collaborator Option. All applicants for the New Investigator Option must meet specific eligibility criteria as described in Section I.C., Eligibility.

Contact Information

• Agency

  Department of Defense

• Office:

  Dept. of the Army -- USAMRAA

• Agency Contact:

  301-682-5507

• Agency Mailing Address:

  CDMRP Help Desk

• Agency Email Address:

  help@cdmrp.org